Showing results (131-140 of 220) with videos related to
Sort By:
Pageof 22
Journal of Clinical Pharmacology|June 17, 2004
Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosingMyong-Jin Kim, Joseph S Bertino, Tara A Erb, et al.The Review of Scientific Instruments|June 6, 2018
Total variation-based neutron computed tomographyRichard C Barnard, Hassina Bilheux, Todd Toops, et al.Antimicrobial Agents and Chemotherapy|May 1, 1999
Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteersK W Garey, C A Peloquin, P G Godo, et al.Clinical Pharmacology and Therapeutics|August 22, 2002
Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarkerMyong-Jin Kim, Joseph S Bertino, Andrea Gaedigk, et al.Journal of Clinical Pharmacology|January 7, 2006
The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probeJoseph D Ma, Anne N Nafziger, Gerry Rhodes, et al.Biorxiv : the Preprint Server for Biology|April 1, 2024
The Role of Ebola Virus VP24 Nuclear Trafficking Signals in Infectious Particle ProductionOlivia A Vogel, Elias Nafziger, Anurag Sharma, et al.Journal of Clinical Pharmacology|August 20, 2004
Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotypingMyong-Jin Kim, Anne N Nafziger, Yanhua Zhang, et al.Clinical Pharmacology in Drug Development|November 8, 2019
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of OliceridineAnne N Nafziger, Kelly A Arscott, Kristina Cochrane, et al.Journal of Clinical Pharmacology|July 17, 2001
Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probeJ S Kim, A N Nafziger, A Gaedigk, et al.Pharmacogenetics|July 4, 2001
Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotypingD S Streetman, A D Kashuba, J S Bertino, et al.Pageof 22